Microbio saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Microbio’s patent filings and grants. Buy the databook here.
Microbio has been focused on protecting inventions in South Korea(KR) with two publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings with nearly 40% of filings. The South Korea(KR), Australia(AU), European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Microbio is filings its patents..
Thermo Fisher Scientific and Danaher could be the strongest competitors for Microbio
Patents related to rare diseases lead Microbio's portfolio
Microbio has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Antibody detection related patents lead Microbio portfolio followed by hypoxia
Microbio has highest number of patents in antibody detection followed by hypoxia.
For comprehensive analysis of Microbio's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.